Macular Degeneration St. George Utah


The modification of peptide, protein, and non-peptide with the linkage of one or more polyethylene glycol (PEG) chains is known as PEGylation. The polymer formed through PEGylation is non-immunogenic, non-antigenic, nontoxic, and highly soluble in water. PEG-drug conjugates offer several advantages over non-conjugated drugs such as elimination or reduction of protein immunogenicity, prolonged half-life, and less degradation by metabolic enzymes. PEGylation was first described by Davies and Abuchowsky in the 1970s. The process has been expanded and developed since then. A wide range of enzymatic and chemical methods for conjugation are available presently. The U.S. FDA has approved various PEGylated therapeutics for the treatment of diseases including autoimmune diseases (multiple sclerosis, gout, and Crohn’s disease), hepatitis C, hepatitis B, cancer, hemophilia, anemia associated with chronic kidney disease, and neovascular age-related macular degeneration. 

PEGylated protein therapeutics is projected to be a highly lucrative market in terms of revenue, with over 10 PEGylated drugs approved by the U.S FDA and 20 drugs in clinical trials. First generation PEGylated drugs were obtained through random PEGylation. Oncaspar and Adagen are two examples. Most of the drugs in clinical trials are PEGylated with larger PEGs compared to first generation therapeutics in order to increase the half-life and decrease the frequency of administration of these therapeutics. Bayer, Novo Nordisk, and Baxalta have a total of four long-acting hemophilia drugs based on PEGylated recombinant coagulation factors in phase III clinical trials. These promising ongoing clinical trials are expected to provide significant opportunities in the market during the forecast period. 

The global PEGylated protein therapeutics market can be segmented based on type of PEGylation, application, distribution channel, and region. In terms of type of PEGylation, the market can be bifurcated into random PEGylation and site specific PEGylation. Based on application, the global PEGylated protein therapeutics market can be classified into cancer, autoimmune diseases, hepatitis, hemophilia, kidney disorder, and others. In terms of distribution channel, the PEGylated protein therapeutics market can be divided into hospital pharmacies, retail pharmacies, and online pharmacies. In terms of region, the global PEGylated protein therapeutics market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. 

Browse more detail information about this report visit at at https://www.transparencymarketresearch.com/pegylated-protein-therapeutics-market.html

North America and Europe are anticipated to be attractive PEGylated protein therapeutics market. Well-established health care infrastructure and funding from public and private sectors for R&D are projected to propel the market in these regions. Acceptance of technologically advanced devices and novel drugs with ongoing clinical trials in PEGylated therapeutics are expected to drive the market in North America. Asia Pacific is expected to account for a significant share of the global market in terms of revenue during the forecast period. Rise in support from governing bodies and the private sector in developing effective and novel therapeutics and distribution network is anticipated to drive the PEGylated protein therapeutics market in the region. Moreover, high prevalence of chronic and rare diseases in Asia Pacific offers large opportunities to players operating in the PEGylated protein therapeutics market. Japan and Australia are well-established markets in Asia Pacific; however, emerging economies such as China and India present significant opportunities in the PEGylated protein therapeutics market in the region. Other regions such as Middle East & Africa and Latin America are anticipated to be prospective markets for PEGylated protein therapeutics in the near future due to the high adoption rate of advanced therapeutics and the rapidly developing health care industry in the regions.

Major players operating in the global PEGylated protein therapeutics market include AstraZeneca plc, Pfizer, Inc., UCB S.A., Amgen, Inc., Merck & Company, Inc., F. Hoffmann-La Roche Ltd., Shire plc, Biogen, Inc., and Horizon Pharma plc.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on: Market segments and sub-segments Market trends and dynamics Supply and demand Market size Current trends/opportunities/challenges Competitive landscape Technological breakthroughs Value chain and stakeholder analysis

Request For Custom Research At https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=53223&source=atm

The regional analysis covers: North America (U.S. and Canada) Latin America (Mexico, Brazil, Peru, Chile, and others) Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg) Eastern Europe (Poland and Russia) Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand) Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report: A complete backdrop analysis, which includes an assessment of the parent market Important changes in market dynamics Market segmentation up to the second or third level Historical, current, and projected size of the market from the standpoint of both value and volume Reporting and evaluation of recent industry developments Market shares and strategies of key players Emerging niche segments and regional markets An objective assessment of the trajectory of the market Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Request for TOC of This Report visit at https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=53223&source=atm



Source link


The Global Ophthalmic Drugs Market Research Report Forecast 2019-2028: The research study has been prepared with the use of in-depth qualitative and quantitative analyses of the global Ophthalmic Drugs Market. The report offers a complete and intelligent analysis of the competition, segmentation, dynamics, and geographical advancement of the Global Ophthalmic Drugs Market. It takes into account the CAGR, value, volume, revenue, production, consumption, sales, Manufacturing cost, prices, and other key factors related to the global Ophthalmic Drugs Market.

The report helps the companies to better understand the Ophthalmic Drugs market trends and to grasp opportunities and articulate critical business strategies. Also includes company profiles of market top companies like (contact information, product details, gross capacity, price, cost and more) are covered. this study of top companies in the market have been identified through secondary research, and their shares have been determined through primary and secondary research. and All percentage shares split, and breakdowns have been determined using secondary sources and verified primary sources.

For Better Understanding – Go With this Free Sample Report Enabled with Respective Tables and Figures https://marketresearch.biz/report/ophthalmic-drugs-market/request-sample

Key Players of the Global Ophthalmic Drugs Market:

Santen Pharmaceutical Co Ltd, Bausch & Lomb Inc (Valeant Pharmaceuticals International Inc), Shire Plc, Alcon (Novartis AG), Genentech Inc, Allergan, Plc, Sun Pharmaceutical Industries Limited, Actavis Generics (Teva Pharmaceutical Industries Ltd.), Regeneron Pharmaceuticals Inc, Pfizer Inc

Market Segmentation:

Segmentation by disease indication:

Dry Eye
Glaucoma
Infection/Inflammation
Retinal Disorders
Wet Age-related Macular Degeneration
Dry Age-related Macular Degeneration
Diabetic Retinopathy
Others
Allergy
Uveitis
Others (includes Optic neuropathy, Eyelash hypotrichosis, etc.)
Segmentation by therapeutic class:

Anti-inflammatory Drugs
Nonsteroidal Anti-inflammatory Drugs
Steroids
Anti-infective Drugs
Anti-fungal Drugs
Anti-bacterial Drugs
Others
Anti-glaucoma Drugs
Alpha Agonist
Beta Blockers
Prostaglandin Analogs
Combined Medication
Others
Anti-allergy Drugs
Anti-VEGF Agents
Others (includes Cyclosporine, etc.)
Segmentation by distribution channel:

Hospital Pharmacies
Online Pharmacies
Independent Pharmacies & Drug Stores

Market Segment by Regions, regional analysis covers 2019-2028:

United States, Canada, and Mexico: North America 

Germany, France, UK, Russia, and Italy: Europe 

China, Japan, Korea, India, and Southeast Asia: Asia-Pacific 

Brazil, Argentina, Colombia, etc.: South America

Saudi Arabia, UAE, Egypt, Nigeria, and South Africa: Middle East and Africa 

Have Any Query Or Specific Requirement? Ask Our Industry Experts https://marketresearch.biz/report/ophthalmic-drugs-market/#inquiry

Table of Content:

Market Overview: The report begins with this section where product overview and highlights of product and application segments of the global Ophthalmic Drugs Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company: Here, the competition in the Worldwide Ophthalmic Drugs Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data: As the name suggests, this section gives the sales data of key players of the global Ophthalmic Drugs Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Ophthalmic Drugs Market.

Market Status and Outlook by Region: In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Ophthalmic Drugs Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User: This section of the research study shows how different end-user/application segments contribute to the global Ophthalmic Drugs Market.

Market Forecast: Here, the report offers a complete forecast of the global Ophthalmic Drugs Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion: This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

Appendix: Here, we have provided a disclaimer, our data sources, data triangulation, research programs, market breakdown and design, and our research approach.

Inquire Here For More Details On this Report or Customizations As Per Your Need https://marketresearch.biz/report/ophthalmic-drugs-market/#request-for-customization

Get in touch with Us:

Mr. Benni Johnson (inquiry@marketresearch.biz)

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States

Website: https://marketresearch.biz



Source link


Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) – Placental growth factor is a protein encoded by the PGF gene. Placental growth factor (PGF) is a member of the VEGF (vascular endothelial growth factor). It plays an important role in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1. PGF is also expressed in many other tissues, including the villous trophoblast.

Sample PDF Brochure @ https://www.reportsintellect.com/sample-request/292291

The report ‘Placenta Growth Factor – Pipeline Review, H2 2018’ outlays comprehensive information on the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 1, 5 and 3 respectively. Report covers products from therapy areas Metabolic Disorders, Ophthalmology and Oncology which include indications Diabetic Macular Edema, Wet (Neovascular / Exudative) Macular Degeneration, Diabetic Retinopathy, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Choroidal Neovascularization, Macular Edema, Retinal Vein Occlusion, Medulloblastoma, Metastatic Colorectal Cancer, Myopia, Neovascular Glaucoma, Non-Proliferative Diabetic Retinopathy (NPDR), Optic Neuropathy and Retinopathy.

Discount PDF Brochure @ https://www.reportsintellect.com/discount-request/292291

Scope

– The report provides a snapshot of the global therapeutic landscape for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)
– The report reviews Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics and enlists all their major and minor projects
– The report assesses Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
– The report summarizes all the dormant and discontinued pipeline projects
– The report reviews latest news and deals related to Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Identify and understand the targeted therapy areas and indications for Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF)
– Identify the use of drugs for target identification and drug repurposing
– Identify potential new clients or partners in the target demographic
– Develop strategic initiatives by understanding the focus areas of leading companies
– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
– Devise corrective measures for pipeline projects by understanding Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) development landscape
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

About Us:-

  • Reports Intellect provides Research Reports for everything related to market research and market intelligence. We understand market importance and its need in today’s competitive world.
  • Our white-collar team works hard to fetch the most authentic research reports backed with perfect data figures which guarantee outstanding results every time for you and your business.
  • Our team is here to help you in the best possible way, whether it is the latest report from the researchers or a custom requirement feel free to contact us.

Contact Us:

Sales@reportsintellect.com

PH – + 1-706-996-2486

US Address:

225 Peachtree Street NE,

Suite 400,

Atlanta, GA 30303



Source link



This may be because of a mistyped URL, a faulty referral from another website, an out of date search engine listing, or the page may have moved. However, we’re happy to write you a referral to visit one of these MDLinx products.

Medical News Articles


All the best medical articles in 32 specialties and 800 subspecialties from over 2,000 peer-reviewed medical journals are summarized, ranked and sorted daily keep you current in less than 5 minutes a day.

Smartest Doc TM


Compete in a daily competition to find out if you’re the Smartest Doc in America! Or, build your personal Review scorecard using thousands of free self-assessment questions to aid exam prep and keep you sharp.

MDLinx Career Center


Search medical job listings and have job opportunities sent directly to your email inbox. Post your CV and have the top medical recruiters bring your dream job to YOU!



Source link


Researchers at the Queensland University of Technology (QUT) have applied artificial intelligence (AI) to develop a more accurate and detailed method for analysing images of the back of the eye to help clinicians better detect and track eye diseases.

In the study, the group of researchers explored a range of deep learning techniques to analyse Optical Coherence Tomography (OCT) images, said David Alonso-Caneiro, QUT senior research fellow and study lead author.

OCT, which takes cross-sectional images of the eye to show different tissue layers, is a common instrument used by optometrists and ophthalmologists. These images are around four microns in size and can help clinicians detect eye diseases such as glaucoma and age-related macular degeneration.

The team collected OCT chorio-retinal eye scans from an 18-month longitudinal study of 101 children with good vision and healthy eyes, and used these images to train the AI program to detect patterns and define the choroid boundaries.

“In our study we looked for a new method of analysing the images and extracting two main tissue layers at the back of the eye, the retina and choroid, with special interest in the choroid. The choroid is the area between the retina and the sclera, and it contains the major blood vessels that provide nutrients and oxygen to the eye,” Alonso-Caneiro said.  

See also: Space medicine -The technology that will keep astronauts alive on their mission to Mars

“The standard imaging processing techniques used with OCT define and analyse the retinal tissue layers well, but very few clinical OCT instruments have software that analyses the choroidal tissue.

“So we trained a deep learning network to learn the key features of the images and to accurately and automatically define the boundaries of the choroid and the retina.”

The study compared the analysis performed by the AI program with standard image analysis methods, which QUT said produced findings that showed the AI was reliable and more accurate in analysing OCT data.

“Notably, all machine learning methods performed substantially better than the automatic baseline on the [retina tests] with respect to both accuracy and consistency with a relatively smaller improvement observed on the inner limiting membrane,” the study said. 

Medicine has been touted as one of the early success stories where humans augmented by machines could literally save lives. As one example, in North Central Pennsylvania, integrated health network Geisinger has developed AI machines that can outperform its cardiologists in analysing electrocardiograms. 

Similarly at the University of Sydney, researchers are developing a customised AI digital health program to prevent heart attacks. The digital health program aims to use patients’ digital footprints recorded in technologies and combine the data with AI to deliver tailored advice, nudges through text messages, and accurate risk assessments to patients who have been to the hospital with chest pains.

The research team at QUT will continue to perform further research to test the program on images from older populations and people with diagnosed diseases.  

Related Coverage



Source link


Epirus Biopharmaceuticals (OTCMKTS:EPRSQ) and Ocular Therapeutix (NASDAQ:OCUL) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Analyst Ratings

This is a breakdown of current ratings and target prices for Epirus Biopharmaceuticals and Ocular Therapeutix, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Epirus Biopharmaceuticals 0 0 0 0 N/A
Ocular Therapeutix 0 1 5 0 2.83

Ocular Therapeutix has a consensus target price of $9.67, indicating a potential upside of 133.49%. Given Ocular Therapeutix’s higher possible upside, analysts clearly believe Ocular Therapeutix is more favorable than Epirus Biopharmaceuticals.

Valuation and Earnings

This table compares Epirus Biopharmaceuticals and Ocular Therapeutix’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Epirus Biopharmaceuticals N/A N/A N/A N/A N/A
Ocular Therapeutix $1.99 million 98.19 -$59.98 million ($1.57) -2.64

Epirus Biopharmaceuticals has higher earnings, but lower revenue than Ocular Therapeutix.

Volatility and Risk

Epirus Biopharmaceuticals has a beta of 6.22, suggesting that its stock price is 522% more volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 2.18, suggesting that its stock price is 118% more volatile than the S&P 500.

Profitability

This table compares Epirus Biopharmaceuticals and Ocular Therapeutix’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Epirus Biopharmaceuticals N/A N/A N/A
Ocular Therapeutix -3,450.84% -256.69% -88.46%

Insider & Institutional Ownership

48.1% of Ocular Therapeutix shares are owned by institutional investors. 13.1% of Epirus Biopharmaceuticals shares are owned by insiders. Comparatively, 16.1% of Ocular Therapeutix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Ocular Therapeutix beats Epirus Biopharmaceuticals on 5 of the 9 factors compared between the two stocks.

Epirus Biopharmaceuticals Company Profile

EPIRUS Biopharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company’s pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis. In addition, it is developing BOW080, a biosimilar version of Soliris for the treatment of ultra-rare blood disorders, including paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and BOW100, a biosimilar version of SIMPONI for the treatment of inflammatory diseases, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, and psoriatic arthritis. The company has a license agreement with Sun Pharmaceutical Industries Ltd.; license and collaboration agreement with Livzon Mabpharm Inc.; and collaboration agreement with Polpharma S.A. The company was founded in 2011 and is headquartered in Boston, Massachusetts. On July 25, 2016, Epirus Biopharmaceuticals, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Massachusetts.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery. Its lead product candidate is DEXTENZA (dexamethasone ophthalmic insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases. The company also develops OTX-TP (intracanalicular travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension; OTX-TIC, an intracameral travoprost implant for the reduction of IOP in patients with moderate to severe glaucoma and ocular hypertension; OTX-TKI, an intravitreal tyrosine kinase inhibitor implant for the treatment of wet age-related macular degeneration(AMD); and OTX-IVT, an intravitreal aflibercept implant for the treatment of wet AMD and other back-of-the-eye diseases. Its various preclinical programs include OTX-BPI for the treatment of acute ocular pain; OTX-BSI to treat post-operative Pain, and inflammation and bacterial infection; OTX-KTO for the treatment of allergy; and OTX-CSI to treat chronic dry-eye. The company has strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company’s sustained-release hydrogel in combination with Regeneron’s large molecule VEGF-targeting compounds to address conditions of the eye. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.

Receive News & Ratings for Epirus Biopharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Epirus Biopharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.



Source link


Based on the Wet Age Related Macular Degeneration (AMD) industrial chain, this report mainly elaborate the definition, types, applications and major players of Wet Age Related Macular Degeneration (AMD) market in details. Deep analysis about market status (2018-2026), enterprise competition pattern, advantages and disadvantages of enterprise Products, industry development trends (2018-2026), regional industrial layout characteristics and macroeconomic policies, industrial policy has also be included. From raw materials to downstream buyers of this industry will be analyzed scientifically, the feature of product circulation and sales channel will be presented as well. In a word, this report will help you to establish a panorama of industrial development and characteristics of the Wet Age Related Macular Degeneration (AMD) market.

This report provides detailed historical analysis of global market for Wet Age Related Macular Degeneration (AMD) from 2019-2026, and provides extensive market forecasts from 2019-2026 by region/country and subsectors. It covers the sales volume, price, revenue, gross margin, historical growth and future perspectives in the Wet Age Related Macular Degeneration (AMD) market.

Interested in this Wet Age Related Macular Degeneration (AMD) market report? Get your FREE sample now! https://www.marketexpertz.com/sample-enquiry-form/43998

Leading players of Wet Age Related Macular Degeneration (AMD) including:

Novartis International (Switzerland), Bayer (Germany), Acucela (U.S.), Neurotech Pharmaceuticals (U.S.), Ophthotech (U.S.), GlaxoSmithKline (U.S.), Alimera Sciences (U.S.), StemCell (Canada), F. Hoffmann-La Roche (Switzerland), Regeneron Pharmaceutical (U.S.), Allergan (Ireland), Adverum Biotechnologies (U.S.), Gilead Sciences (U.S.)

Objective of Studies:

  1. To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the global Wet Age Related Macular Degeneration (AMD) market.
  2. To provide insights about factors affecting the market growth. To analyze the Wet Age Related Macular Degeneration (AMD) market based on various factors- price analysis, supply chain analysis, Porte five force analysis etc.
  3. To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, Latin America and Rest of the World.
  4. To provide country level analysis of the market with respect to the current market size and future prospective.
  5. To provide country level analysis of the market for segment by application, product type and sub-segments.
  6. To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.
  7. To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Wet Age Related Macular Degeneration (AMD) market.

Some niche products and services believed to be revenue generators are also included in the report. Apart from this, a wide range of products from various segments and sub-segments expected to present greater opportunities in the Wet Age Related Macular Degeneration (AMD) industry are discussed in the document. Development of new products and substitutes that will completely transform the market dynamics over the forecast period occupies a special section in the report.

You Can Download Free Sample PDF Copy of Wet Age Related Macular Degeneration (AMD) Market https://www.marketexpertz.com/sample-enquiry-form/43998

Market segmentation, by product types:

  • Wet Age-Related Macular Degeneration (Wet AMD)
  • Dry Age-Related Macular Degeneration (Dry AMD)

Market segmentation, by applications:

  • >75 Years
  • >60 Years
  • >40 Years

Market segment by Region/Country including:

  • North America (United States, Canada and Mexico)
  • Europe (Germany, UK, France, Italy, Russia and Spain etc.)
  • Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.)
  • South America Brazil, Argentina, Colombia and Chile etc.)
  • Middle East & Africa (South Africa, Egypt, Nigeria and Saudi Arabia etc.)

The report can answer the following questions:

  1. What is the global (North America, South America, Europe, Africa, Middle East, Asia, China, Japan) production, production value, consumption, consumption value, import and export of Wet Age Related Macular Degeneration (AMD)?
  2. Who are the global key manufacturers of Wet Age Related Macular Degeneration (AMD) industry? How are their operating situation (capacity, production, price, cost, gross and revenue)?
  3. What are the types and applications of Wet Age Related Macular Degeneration (AMD)? What is the market share of each type and application?
  4. What are the upstream raw materials and manufacturing equipment of Wet Age Related Macular Degeneration (AMD)? What is the manufacturing process of Wet Age Related Macular Degeneration (AMD)?
  5. Economic impact on Wet Age Related Macular Degeneration (AMD) industry and development trend of Wet Age Related Macular Degeneration (AMD) industry.
  6. What will the Wet Age Related Macular Degeneration (AMD) market size and the growth rate be in 2026?
  7. What are the key factors driving the global Wet Age Related Macular Degeneration (AMD) industry?
  8. What are the key market trends impacting the growth of the Wet Age Related Macular Degeneration (AMD) market?
  9. What are the Wet Age Related Macular Degeneration (AMD) market challenges to market growth?
  10. What are the Wet Age Related Macular Degeneration (AMD) market opportunities and threats faced by the vendors in the global Wet Age Related Macular Degeneration (AMD) market?

Get Access to Full summary of this [email protected] https://www.marketexpertz.com/industry-overview/2019-wet-age-related-macular-degeneration-amd-market



Source link


Coherent Market Insights released a new market study on 2018-2026 Optogenetics Actuators & Sensors Market with 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. Report offering you more creative solutions that combine our deep geographic experience, intimate sector knowledge and clear insights into how to create value in your business. The research study provides estimates for 2018-2026 Optogenetics Actuators & Sensors Market Forecast till 2026*.

Download PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2378

Synopsis – Optogenetics Actuators & Sensors Market Research Report covers insights of Optogenetics Actuators & Sensors industry over past five to eight years and forecast until 2018-2026. Optogenetics Actuators & Sensors Market report helps to analyse competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global Optogenetics Actuators & Sensors Market 2018 Industry Trend and Forecast 2026

Market Dynamics:

Factors responsible for growth of the optogenetics actuators & sensors market are rise in burden of retinal disease and neurological disorders, rapid development and research in the field of optogenetics, and government initiatives such as funding support for development of this field. Optogenetics allow to understand which biochemical and physiological pathway is working for cause of particular disease, which may help to find treatment for particular disease by flashing blue light on specific neural cells. According to World Health Organization’s factsheet in 2016, age-related macular degeneration (AMD) ranked third among the global causes of visual impairment with a blindness prevalence of 8.7 %. Age-related macular degeneration is the primary cause of visual deficiency in industrialized countries. Alzheimer’s disease is another potential area in which optogenetics could give sustainable treatment solution. According to World Alzheimer Report in 2016, there were an estimated 46.5 million Alzheimer’s disease patients across the world. Moreover, every three second, one new case of Alzheimer’s disease is registered, worldwide.

Optogenetics Actuators & Sensors Market report provides key statistics on the Market status of the Optogenetics Actuators & Sensors manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the Optogenetics Actuators & Sensors industry. The Optogenetics Actuators & Sensors Market report also presents the vendor landscape and a corresponding detailed analysis of the major vendors operating in the Market.

Top Key Players of Optogenetics Actuators & Sensors Market: are Bruker, Circuit Therapeutics, Inc., Gensight Biologics, AGTC, Prizmatix, Merck KGaA, Elliot Scientific Ltd., Coherent, Inc., The Jackson Laboratory, Scientifica (Judges Scientific Plc Company), Addgene, Shanghai Laser & Optics Century Co., Ltd. (SLOC), Noldus Information Technology, Thorlabs, Inc., and Danaher.

Regions of Optogenetics Actuators & Sensors Market:

North America: United States, Canada, Mexico
Europe: Germany, France, UK, Russia, Italy, Rest of Europe
Middle East Africa: Turkey, Egypt, South Africa, GCC Countries, Rest of Middle East & Africa
Asia-Pacific: China, India, Australia, Japan, South Korea, Indonesia, Malaysia, Philippines, Thailand, Vietnam

In the end, the report makes some important proposals for a new project of Optogenetics Actuators & Sensors Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of global Optogenetics Actuators & Sensors industry covering all important parameters.

• Optogenetics Actuators & Sensors Driver
• Optogenetics Actuators & Sensors Challenge
• Optogenetics Actuators & Sensors Trends

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/2378

Further, in the Optogenetics Actuators & Sensors Market research report, the following points are included along with an in-depth study of each point:

Production Analysis – Production of the Optogenetics Actuators & Sensors is analyzed with respect to different regions, types, and applications. Here, price analysis of various Optogenetics Actuators & Sensors Market key players is also covered.

Sales and Revenue Analysis – Both, sales and revenue are studied for the different regions of the global Optogenetics Actuators & Sensors Market. another major aspect, price, which plays an important part in the revenue generation is also assessed in this section for the various regions.

Supply and Consumption – In continuation with sales, this section studies supply and consumption for the Optogenetics Actuators & Sensors Market. This part also sheds light on the gap between supply and consumption. Import and export figures are also given in this part.

Other analyses – Apart from the information, trade and distribution analysis for the Optogenetics Actuators & Sensors Market, contact information of major manufacturers, suppliers and key consumers are also given. Also, SWOT analysis for new projects and feasibility analysis for new investment are included.

• In continuation with this data, the sale price is for various types, applications and region is also included. The Optogenetics Actuators & Sensors Market for major regions is given. Additionally, type wise and application wise consumption figures are also given.

Optogenetics Actuators & Sensors Market – Market Taxonomy

On the basis of actuators, the global optogenetics actuators & sensors market is segmented into

  • Channelrhodopsin
  • Halorhodopsin
  • Archaerhodopsin

On the basis of sensors, the global optogenetics actuators & sensors market is segmented into

  • Genetically Encoded Calcium Indicators
  • Voltage-Sensitive Fluorescent Proteins
  • pH Sensors

On the basis of devices, the global optogenetics actuators & sensors market is segmented into

  • Light Emitting Diode
  • Lasers
  • Others

On the basis of applications, the optogenetics actuators & sensors market is segmented into

  • Retina related disorder
  • Neural disorder
  • Psychological disorder
  • Others

On the basis of geography, the optogenetics actuators & sensors market is segmented into:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

In this study, the years considered to estimate the market size of 2018-2026 Optogenetics Actuators & Sensors Market are as follows:

History Year: 2015-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2026

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.



Source link


Global Macular Degeneration AMD and Diabetic Retinopathy DR Drugs Market Report available at Brand Essence Research gives an overview of the Macular Degeneration AMD and Diabetic Retinopathy DR Drugs industry which covers product scope, market revenue, opportunities, growth rate, sales volumes and figures. The report also explores the worldwide players of the market and is segmented by region, type and application with forecast to 2024.

In this report, we analyze the Macular Degeneration AMD and Diabetic Retinopathy DR Drugs industry from two aspects. One part is about its production and the other part is about its consumption. In terms of its production, we analyze the production, revenue, gross margin of its main manufacturers and the unit price that they offer in different regions from 2014 to 2019. In terms of its consumption, we analyze the consumption volume, consumption value, sale price, import and export in different regions from 2014 to 2019. We also make a prediction of its production and consumption in coming 2019-2024.

Request a sample Report of Macular Degeneration AMD and Diabetic Retinopathy DR Drugs Market at: https://brandessenceresearch.biz/Request/Sample?ResearchPostId=98863&RequestType=Sample

Finally, the feasibility of new investment projects is assessed, and overall research conclusions are offered.

Key players in global Macular Degeneration AMD and Diabetic Retinopathy DR Drugs market include:

Novartis, Bayer Healthcare, Roche, Neurotech Pharmaceuticals, Regeneron Pharmaceuticals, Allergan

The report can answer the following questions:

  1. What is the global (North America, South America, Europe, Africa, Middle East, Asia, China, Japan) production, production value, consumption, consumption value, import and export of Texture Curing Machine?
  2. Who are the global key manufacturers of Macular Degeneration AMD and Diabetic Retinopathy DR Drugs industry? How are their operating situation (capacity, production, price, cost, gross and revenue)?
  3. What are the types and applications of Texture Curing Machine? What is the market share of each type and application?
  4. What are the upstream raw materials and manufacturing equipment of Texture Curing Machine? What is the manufacturing process of Texture Curing Machine?
  5. Economic impact on Macular Degeneration AMD and Diabetic Retinopathy DR Drugs industry and development trend of Macular Degeneration AMD and Diabetic Retinopathy DR Drugs industry.
  6. What will the Macular Degeneration AMD and Diabetic Retinopathy DR Drugs market size and the growth rate be in 2024?
  7. What are the key factors driving the global Macular Degeneration AMD and Diabetic Retinopathy DR Drugs industry?
  8. What are the key market trends impacting the growth of the Macular Degeneration AMD and Diabetic Retinopathy DR Drugs market?
  9. What are the Macular Degeneration AMD and Diabetic Retinopathy DR Drugs market challenges to market growth?
  10. What are the Macular Degeneration AMD and Diabetic Retinopathy DR Drugs market opportunities and threats faced by the vendors in the global Macular Degeneration AMD and Diabetic Retinopathy DR Drugs market?

Ask for Customization on Macular Degeneration AMD and Diabetic Retinopathy DR Drugs Market Report at: https://brandessenceresearch.biz/Request/Sample?ResearchPostId=98863&RequestType=Customization

Market segment by Type, the product can be split into

Macular Degeneration Drugs, Diabetic Retinopathy Drugs

Market segment by Application, split into

50-60 Years Old, 60-70 Years Old, Other

Market segment by Regions/Countries, this report covers

United States

Europe

China

Japan

Southeast Asia

India

Central & South America

Objective of Studies:

  1. To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the global Macular Degeneration AMD and Diabetic Retinopathy DR Drugs market.
  2. To provide insights about factors affecting the market growth. To analyze the Macular Degeneration AMD and Diabetic Retinopathy DR Drugs market based on various factors- price analysis, supply chain analysis, Porte five force analysis etc.
  3. To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, Latin America and Rest of the World.
  4. To provide country level analysis of the market with respect to the current market size and future prospective.
  5. To provide country level analysis of the market for segment by application, product type and sub-segments.
  6. To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.
  7. To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Macular Degeneration AMD and Diabetic Retinopathy DR Drugs market.

For More Details On this Report: https://brandessenceresearch.biz/Medical-Devices-and-Consumables/Global-Macular-Degeneration-AMD-and-Diabetic-Retinopathy-DR-Drugs-Industry-Market-Research-2019/Summary

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Contact US:

https://brandessenceresearch.biz/

Brandessence Market Research & Consulting Pvt ltd.

Kemp House, 152 – 160 City Road, London EC1V 2NX

+44-2038074155

sales@brandessenceresearch.com



Source link


Global Ocular Drug Delivery Technology Market Size, Status And Forecast 2019-2025

The report provides a unique tool for evaluating the market, highlighting opportunities, and supporting strategic and tactical decision-making. This report recognizes that in this rapidly-evolving and competitive environment, up-to-date Marketing information is essential to monitor performance and make critical decisions for growth and profitability. It provides information on trends and developments, and focuses on market, capacities and technologies and on the changing structure of the Ocular Drug Delivery Technology.

Avail a Sample Copy before Purchase:

https://www.marketinsightsreports.com/reports/06211315303/global-ocular-drug-delivery-technology-market-size-status-and-forecast-2019-2025/inquiry?source=socioherald&Mode=48   

Top Leading Companies are: OCULAR THERAPEUTIX, Alimera Sciences, Allergan, Valeant Pharmaceuticals International, EyeGate Pharma, Envisia Therapeutics, Clearside Biomedical, Graybug Vision, Santen Pharmaceutical, Taiwan Liposome Company

Market segment by Type, the product can be split into:
Glaucoma
Macular Degeneration
Diabetic Retinopathy
Cataract
Diabetic Macular Edema
Dry Eye Syndrome
Others

Market segment by Application, split into:
Hospitals
Ambulatory Surgical Centers
Ophthalmic Clinics
Homecare Settings

SPECIAL OFFER (Avail a flat 15% discount on this report, please fill the form and mention the code: MIR15 in the comments section):

https://www.marketinsightsreports.com/reports/06211315303/global-ocular-drug-delivery-technology-market-size-status-and-forecast-2019-2025/discount?source=socioherald&Mode=48  

Influence of the Ocular Drug Delivery Technology market report:

-Comprehensive assessment of all opportunities and risk in the Ocular Drug Delivery Technology market.

-Ocular Drug Delivery Technology market recent innovations and major events.

-Detailed study of business strategies for growth of the Ocular Drug Delivery Technology market-leading players.

-Conclusive study about the growth plot of market for forthcoming years.

-In-depth understanding of market-particular drivers, constraints and major micro markets.

-Favorable impression inside vital technological and market latest trends striking the market.

Important Features that are under Offering and Key Highlights of the Reports:

– Detailed overview of Market

– Changing market dynamics of the industry

– In-depth market segmentation by Type, Application etc

– Historical, current and projected market size in terms of volume and value

– Recent industry trends and developments

– Competitive landscape of Market

– Strategies of key players and product offerings

– Potential and niche segments/regions exhibiting promising growth

Buy this Report: 

https://www.marketinsightsreports.com/report/purchase/06211315303?mode=su?source=socioherald&Mode=48  

The report will make detailed analysis mainly on the development environment, market size, and development trends of Ocular Drug Delivery Technology market on the basis of current situation of the industry in 2019 so as to get a holistic understanding of the competition in Ocular Drug Delivery Technology Market Carrier.

If you have any special requirements, please let us know and we will offer you the report as you want.

Contact Us:

Irfan Tamboli (Head of Sales)                                      

Market Insights Reports

Phone: + 1704 266 3234

Mob: +91-750-707-8687

[email protected]

[email protected]



Source link